76 TWENTYFOURSEVENBIOPHARMA Issue 1 / March 2026 constraints, sponsors win by combining capability‑led partner selection with transparent risk governance and resilient dual‑path supply architectures. Keep Plan A, qualify Plan B, and make partners show their work. That’s how you protect timelines, approvals, and long‑term supply security.7 The most efficient and successful CDMO collaborations share a common theme: clear, complete, and timely information from the start. Will there be issues? Of course, it is chemistry. How your CDMO handles the problems is what tells you all you need to know. A true partner is what you should look for not just a pair of hands with large reactor capacity. References 1. Pharma Manufacturing (William Blair), “Analysts are bullish on 2026 growth outlook for CDMOs,” Nov 4, 2025. https://www.pharmamanufacturing. com/sector/contract-manufacturing/ article/55327913/analysts-are-bullish-on-2026growth-outlook-for-cdmos 2. Pharmaceutical Commerce, “New Report Cautions That China’s Pharma Dominance Poses Growing Risks,” Nov 19, 2025. https:// www.pharmaceuticalcommerce.com/view/newreport-cautions-china-pharma-dominance-posesgrowing-risks-us-drug-supply-chain 3. PharmaSource, “Stop Letting CDMOs Tell You What You Want to Hear,” Feb 2026. https:// pharmasource.global/content/stop-lettingcdmos-tell-you-what-you-want-to-hear/ 4. CSIS ChinaPower Podcast, “China’s Influence in Pharmaceutical Supply Chains,” Aug 14, 2025. https://www.csis.org/podcasts/chinapower/ chinas-influence-pharmaceutical-supply-chainsconversation-dr-yanzhong-huang 5. PharmaSource Podcast, “How Private Equity Capital Flows are Reshaping the CDMO Landscape,” July 21, 2025. https://pharmasource. global/content/podcast/how-private-equitycapital-flows-are-reshaping-the-cdmolandscape/ 6. FDA, “Public Meeting: Onshoring Manufacturing of Drugs and Biological Products,” Sept 30, 2025. https://www.fda.gov/drugs/newsevents-human-drugs/fda-public-meetingonshoring-manufacturing-drugs-and-biologicalproducts-09302025 7. CSIS, “Rebuilding Resilience in U.S. Pharmaceutical Manufacturing,” Sept 29, 2025. https://www.csis.org/analysis/rebuildingresilience-us-pharmaceutical-manufacturing 8. STAT, “Forced onshoring of biosimilar, generic manufacturing threatens efficiency,” Oct 6, 2025. https://www.statnews.com/2025/10/06/ onshoring-tariffs-pharmaceuticals-biosimilarsgenerics-efficiency/ 9. BOMA International, “Pharma’s Onshoring Movement,” July 24, 2025. https://boma.org/ resource/pharmas-onshoring-movement/ 10. Pharmaceutical Manufacturing, “Drugmakers and CDMOs seize GLP‑1 opportunity, invest in manufacturing facilities,” Mar 7, 2026. https:// megaproject.com/news/factory/drugmakersand-cdmos-seize-glp-1-opportunity-invest-inmanufacturing-facilities 11. CordenPharma, “€900m Peptide Platform Expansion in USA & Europe,” July 16, 2024. https://cordenpharma.com/articles/pressrelease-cordenpharma-invests-900-millioneuros-in-transformational-peptide-platformexpansion-in-usa-and-europe/ 12. Drug Development & Delivery, “Neuland to Open Commercial Peptide Facility as part of Planned Phased Expansion,” Mar 2026. https:// drug-dev.com/neuland-to-open-commercialpeptide-facility-as-part-of-planned-phasedexpansion/ 13. PharmaSource, “Neuland Laboratories Plans Commercial Peptide Manufacturing Facility Opening in Summer 2026,” Mar 10, 2026. https://pharmasource.global/content/news/ cdmo-news/neuland-laboratories-planscommercial-peptide-manufacturing-facilityopening-in-summer-2026/ 14. Contract Pharma, “API Manufacturing: Key Trends Reshaping the Global Market,” Feb 4, 2026. https://www.contractpharma.com/ api-manufacturing-key-trends-reshaping-theglobal-market/ 15. PharmaSource, “Drive‑thru? Online? In person? How to place an order (for your small molecule),” May 2025. https://pharmasource. global/content/expert-insight/drive-thruonline-in-person-how-to-place-an-order-foryour-smallmolecule/ KENNETH DREW Vice President Flamma USA FLAMMA
RkJQdWJsaXNoZXIy MjY2OTA4MA==